Epidemiological characteristics and trend of HBV-DNA changes in patients with hepatitis B and liver cancer in Nantong region
10.3969/j.issn.1006-2483.2024.04.023
- VernacularTitle:南通地区乙型肝炎肝癌患者的流行病学特征及HBV-DNA变化趋势
- Author:
Chi ZHANG
1
;
Qingxia MA
1
;
Yifeng GU
1
Author Information
1. Laboratory Department of Nantong Cancer Hospital , Nantong , Jiangsu 226361 , China
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Liver cancer;
Hepatitis B virus;
Family history
- From:
Journal of Public Health and Preventive Medicine
2024;35(4):95-98
- CountryChina
- Language:Chinese
-
Abstract:
Objective Based on the epidemic situation of hepatitis B and liver cancer patients in Nantong from 2019 to 2022, to analyze the trend of hepatitis B virus DNA (HBV-DNA) changes and provide theoretical basis for the prevention and treatment of hepatitis B and liver cancer. Methods The data of patients with hepatitis B and liver cancer in Nantong Cancer Hospital were collected, and the general data, the time of infection with hepatitis B and the results of quantitative HBV-DNA test were statistically analyzed. Results A total of 487 patients with hepatitis B and liver cancer were collected, including 395 males and 92 females. Among them, patients aged 51-60 were the most common, accounting for 28.34%, followed by those aged 41-50 and 61-70, accounting for 23.00% and 21.56% respectively. In addition to 84 patients with unknown infection time, most of the patients with hepatitis B infection time distributed in 11 to 20 years, followed by 21 to 30 years and 1 to 10 years. Except for 126 patients with unknown levels of HBV DNA, the positive rate of HBV DNA in 361 patients was 64.82%. Between 2019 and 2022, except for patients with unknown levels of HBV-DNA, the proportion of patients with HBV-DNA<500 copies/mL showed an upward trend, while the proportion of patients with HBV-DNA (103-106) copies/mL showed a downward trend. Conclusion Sex and the time of infection with hepatitis B are high risk factors for hepatitis B liver cancer. Most patients with liver cancer are positive for HBV-DNA, which needs to be tested regularly to guide antiviral treatment.
